Wearable Continuous Glucose Monitoring Devices Market Size
Wearable Continuous Glucose Monitoring Devices Market reached USD 13.46 billion in 2025 and is expected to reach US$32.48 billion by 2033, growing at a CAGR of 10.3% during the forecast period 2026-2033, according to DataM intelligence research.
As per our analysis, the wearable continuous glucose monitoring devices market is experiencing lucrative growth due to the rising prevalence of diabetes, increasing awareness among the diabetes population on disease management, and rising innovations from key market players. However, the affordability issues in the low and middle-income countries, accuracy, and calibration issues can hinder the adoption of CGMs at the anticipated rate.
Wearable Continuous Glucose Monitoring Devices Market Key Takeaways
- The wearable continuous glucose monitoring devices market is projected to reach USD 32.48 billion by 2033, reflecting sustained demand for real-time diabetes management technologies.
- Rising diabetes prevalence remains the primary demand catalyst, with 588.71 million people living with diabetes globally in 2025, creating a large addressable patient population.
- Sensors accounted for 71.4% of total market revenue in 2025, highlighting their recurring revenue potential due to periodic replacement requirements.
- North America captured 53.4% of the global market in 2025, supported by strong reimbursement systems, regulatory approvals, and broad commercialization of advanced CGM products.
- Product innovation is shifting toward longer-lasting sensors, smaller wearable devices, and over-the-counter glucose monitoring solutions that expand accessibility beyond insulin users.
- Accuracy limitations, calibration requirements, and affordability constraints continue to influence purchasing decisions, particularly across emerging economies.
Wearable Continuous Glucose Monitoring Devices Market Scope
| Metrics | Details |
| Market Size (2025) | USD 13.46 Billion |
| Market Size (2033) | USD 32.48 Billion |
| CAGR(2026-2033) | 10.3% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Component, Indication, Age Group, Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
Executive Summary
For more details on this report – Request for Sample
Wearable Continuous Glucose Monitoring Devices Market Dynamics: Drivers & Restraints
The growing prevalence of diabetes is driving the market growth
Wearable glucose monitoring devices are gaining huge popularity due to their ability to track the patient's glucose levels continuously and enable the physician/patient to make timely decisions. With the rising prevalence of diabetes and increasing awareness of disease management, the demand for continuous glucose monitoring devices is on the rise.
For instance, according to the International Diabetes Federation, in 2024, globally, 588.71 million people are living with diabetes, and by 2050, this number is expected to reach 852.47 million. Among these people, the adoption of wearable continuous glucose monitoring devices is rapidly growing. The presence of key market players such as Abbott, Dexcom, Inc., who have gained popularity in the diabetes devices landscape, and their constant innovations to fulfill the high unmet needs are expected to further boost the market growth.
Accuracy and calibration issues may restrain the market growth
The continuous glucose monitoring systems are gaining huge popularity these days, however, they often have accuracy and calibration issues. These devices can sometimes produce deviated results from the actual blood glucose levels. As CGMs primarily rely on interstitial fluid glucose measurement, which can lag behind blood glucose changes by several minutes. As a result, users may experience discrepancies during rapid glucose fluctuations, such as after meals or exercise. Moreover, faulty sensors or transmitter components can hinder the device readings. These devices have to be calibrated on a timely basis to ensure their proper functioning. This can be a cumbersome activity for users and may lead to decreased adoption.
Wearable Continuous Glucose Monitoring Devices Market Opportunities
Growing acceptance of preventive healthcare and digital disease management presents new opportunities for wearable continuous glucose monitoring manufacturers. The availability of over-the-counter glucose monitoring systems expands the addressable market beyond traditional insulin users to include individuals with prediabetes and lifestyle-related metabolic conditions.
Manufacturers have additional opportunities to differentiate through longer-lasting sensors, mobile health applications, cloud-based patient monitoring platforms, and improved integration with broader digital healthcare ecosystems. Companies capable of balancing clinical accuracy with affordability will be better positioned to expand penetration across emerging healthcare markets.
Wearable Continuous Glucose Monitoring Devices Market Segment Analysis
The global wearable continuous glucose monitoring devices market is segmented based on component, indication, age group, and region.
Sensors in the component segment accounted for 71.4% of the market share in 2025 in the global wearable continuous glucose monitoring devices market
The sensors component plays a crucial role in wearable continuous glucose monitoring (CGM) devices, as they provide real-time, accurate glucose measurements. Sensors are the core technology behind CGMs, as they continuously monitor blood glucose levels in interstitial fluid, offering users detailed and up-to-date information. With the increasing demand for more precise, real-time monitoring, advancements in sensor technology have enabled the development of more accurate, smaller, and longer-lasting devices.
Patients who are using continuous glucose monitoring devices must buy sensors regularly, as they are intended to be used for once. Several sensors from different manufacturers have varying lifespans, which can range from days to weeks. For instance, Abbott FreeStyle Libre 2, Abbott FreeStyle Libre 14-day, Abbott FreeStyle Libre 3 sensors have a lifespan of 14 days, Abbott FreeStyle Libre 2 Plus, Abbott FreeStyle Libre 3 Plus sensors have a lifespan of 15 days, Dexcom G6, Dexcom G7 sensors have a lifespan of 10 days, Medtronic Guardian Connect sensors have a lifespan of 7 days, whereas Eversense 365 CGM System sensors have a lifespan of 365 days. Once the sensors are utilized for a designated period, they must be replaced with new ones. Hence, a major portion of the overall spending of consumers on a CGM system goes to sensors. Moreover, key manufacturers in the market generate a major portion of their revenue from the sale of sensors.
Moreover, innovations in sensor design, such as improved accuracy, reduced size, and extended wear times, are driving the segment's growth. For instance, in August 2024, Dexcom launched Stelo, a new biosensor for adults with prediabetes and type 2 diabetes who do not use insulin. This is the first glucose measuring biosensor to be available in the United States over the counter. As people with diabetes seek more efficient and convenient ways to manage their condition, the demand for CGM systems with advanced sensors is growing. This makes the sensors segment a key driver in the wearable CGM market, as it directly impacts the overall performance and reliability of these devices.
Wearable Continuous Glucose Monitoring Devices Market Geographical Analysis
North America dominated the wearable continuous glucose monitoring devices market with the highest share of 53.4% in 2025
The North America region dominates the wearable continuous glucose monitoring devices due to various factors such as higher prevalence of diabetes, strong availability of advanced CGM systems, high purchasing power of consumers, favourable reimbursement policies, and constant innovations and product launches from market players.
For instance, according to International Diabetes Federation statistics, nearly 38 million people in the United States were living with diabetes in 2024, and by 2050, the diabetes population is expected to reach 42 million. This rising prevalence of diabetes drives the demand for advanced monitoring devices like continuous monitoring systems.
Additionally, market players are constantly innovating the advanced wearable CGMs that are gaining approvals from the Food and Drug Administration (FDA). For instance, in April 2025, the U.S. FDA approved DexCom, Inc.’s G7 15-Day continuous glucose monitoring system, designated for use in people over the age of 18 with diabetes in the United States. In March and June 2024, Dexcom and Abbott received clearance from the Food and Drug Administration (FDA) for their over-the-counter (OTC) continuous glucose monitors. Increasing approvals for products, such as over-the-counter continuous glucose monitors, are expected to drive the region’s market by expanding accessibility to glucose monitoring solutions. This will cater to a broader range of users, including those without insulin dependence. Thus, the above factors are expected to hold the region in the dominant position.
Wearable Continuous Glucose Monitoring Devices Market Major Players
The major players in the Wearable continuous glucose monitoring devices market are Dexcom, Inc., Abbott., Medtronic, Senseonics, F. Hoffmann-La Roche Ltd, and Afon Technology., among others.
Wearable Continuous Glucose Monitoring Devices Market Key Developments
June 2026: Dexcom expanded its wearable continuous glucose monitoring (CGM) portfolio by introducing next-generation AI-enabled glucose monitoring solutions with enhanced sensor accuracy, extended wear duration, and seamless integration with digital diabetes management platforms.
May 2026: Abbott strengthened its FreeStyle Libre ecosystem by enhancing wearable CGM technology with improved connectivity, real-time glucose analytics, and expanded compatibility with insulin delivery systems to support personalized diabetes care.
April 2026: Medtronic advanced its continuous glucose monitoring platform by integrating wearable CGM devices with AI-powered insulin management algorithms, enabling more precise glucose control and improving outcomes for people with diabetes.
March 2026: Senseonics enhanced its implantable and wearable glucose monitoring technologies by expanding long-term continuous glucose sensing capabilities and strengthening remote patient monitoring features for diabetes management.
February 2026: Roche expanded its digital diabetes care portfolio by integrating wearable continuous glucose monitoring technologies with cloud-based analytics and connected health platforms, enabling real-time glucose tracking and data-driven clinical decision-making.
Market Impact Analysis
Regulatory approvals continue to influence commercialization across the wearable continuous glucose monitoring devices market by expanding access to prescription-free monitoring solutions and supporting broader patient adoption.
At the same time, the recurring requirement for sensor replacement creates predictable revenue streams for manufacturers but also contributes to affordability concerns in cost-sensitive healthcare systems. Improving sensor durability, extending wear periods, and reducing ownership costs will remain important priorities for expanding market penetration globally.
Report Benefits
This report supports strategic decision-making by providing:
- Market size, growth outlook, and revenue forecast through 2035.
- Competitive benchmarking of leading wearable continuous glucose monitoring device manufacturers.
- Assessment of component, indication, age group, and regional growth opportunities.
- Evaluation of technology trends, product innovation, and regulatory developments.
- Commercial insights for manufacturers, investors, procurement teams, healthcare providers, and strategic planners.
Target Audience
- Wearable medical device manufacturers
- Continuous glucose monitoring device developers
- Diabetes care companies
- Healthcare providers and hospital networks
- Investors and venture capital firms
- Medical technology companies
- Healthcare distributors
- Regulatory and policy organizations
- Procurement and sourcing teams
- Market intelligence and corporate strategy professionals
Conclusion
The wearable continuous glucose monitoring devices market is positioned for sustained expansion through 2035 as diabetes prevalence continues to increase and continuous glucose monitoring becomes a standard component of long-term disease management. Advances in wearable biosensors, longer-lasting sensors, over-the-counter product availability, and improved digital connectivity are expanding commercial opportunities across both established and emerging patient populations.
Manufacturers that continue improving sensor accuracy, reducing ownership costs, extending device lifespan, and broadening accessibility are expected to strengthen their competitive position. While affordability and calibration challenges remain important considerations, ongoing product innovation, favorable regulatory support, and expanding patient awareness create a solid foundation for long-term market growth.
